Pioglitazone + azilsartan

Pioglitazone + azilsartan is a fixed-dose combination of two small molecule drugs used for the management of type 2 diabetes mellitus and potentially hypertension. Pioglitazone is a thiazolidinedione that acts as an insulin sensitizer by increasing the body's sensitivity to insulin, thereby improving glycemic control in patients with type 2 diabetes[1][5]. Azilsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, leading to vasodilation and reduced blood pressure by blocking the effects of angiotensin II[3][5][6]. The combination aims to address both hyperglycemia and comorbid hypertension commonly seen in diabetic patients. This specific combination was investigated in clinical trials but development was terminated[5].